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Introduction and objective. Gastrointestinal complications are considered as one of the 
most common manifestations in patients with Common Variable Immunodeficiency (CVID). 
These complications can result from Small Intestinal Bacterial Overgrowth (SIBO). Hydrogen 
breath test is extensively used to diagnose SIBO. The objective of this study was to evaluate 
the prevalence of SIBO using the Hydrogen Breath Test (HBT) in patients with CVID. Ma-
terials and methods. Twenty-seven patients with CVID entered this cross-sectional study. 
Demographic and lower gastrointestinal symptoms were recorded in a check list. Hemoglobin 
level was measured in all patients. The concentration of IgA and IgG was assessed using nephe-
lometry. Moreover, SIBO was detected by means of Glucose hydrogen breath test.  Results. The 
mean (± SD) age of the patients was 35.25 (± 11.69) years.  Twenty patients (74.1%) man-
ifested at least one lower gastrointestinal symptom. The most frequent lower gastrointestinal 
manifestations were bloating (66.7%) and chronic diarrhea (40.7%), respectively. IgA level 
less than 10 mg/dl and IgG level less than 600 mg/dl were determined in 77.8% and 25.9% 
of patients, respectively. Positive HBT was detected in 40.7% (n = 11) of the patients.  In the 
positive HBT group, bloating, chronic diarrhea and abdominal pain were the most common 
lower GI manifestations. There was no significant difference in terms of age, BMI, IgA level, 
and duration of CVID between the positive and negative HBT groups. The significant associ-
ation of co-occurrence of anemia and abdominal pain with positive HBT (positive predictive 
value: 100%) might be considered as a clue to SIBO diagnosis. Conclusions. Regarding the 
high prevalence and non-specific manifestation of SIBO, it is suggested to consider concurrent 
symptoms in patients with CVID to manage the timely and precise diagnosis of SIBO.
Introduction
Primary Immunodeficiency Diseases (PIDs) as a group of het-
erogeneous disorders are characterized by inability of the im-
mune system to protect the body against foreign hazards (1, 2). 
Gastrointestinal (GI) problems are ranked as the second com-
mon manifestations in PID patients (2). It is noteworthy that 
GI complications are variable in different PIDs as well as differ-
ent individuals (2).
Common Variable Immunodeficiency (CVID) as a heterogeneous 
Primary Immunodeficiency Disease (PID) with a prevalence of 1 in 
25,000 to 50,000 is characterized by hypogammaglobulinemia, fail-
ure to produce immunoglobulin against vaccines and recurrent bac-
terial infections (3-5). Increased susceptibility to bacterial infections 
in respiratory and gastrointestinal tracts has been reported in more 
than 90% of patients with CVID (6). Given that the gastrointestinal 
tract contains a lymphatic system, it can be involved up to 50% of 
primary immunodeficiency diseases (5). Gastrointestinal manifes-
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tations are infections, inflammation, autoimmunity, and cancers 
(5). These gastrointestinal symptoms have different pathogenesis 
and do not often improve following conventional treatments (5). 
Previous studies have reported acute or chronic diarrhea as the most 
frequent gastrointestinal manifestations ranged from 20 to 60% in 
patients with CVID (7-9). The causes of chronic diarrhea in these 
patients are microbial and non-microbial. One of the major causes 
of diarrhea in these patients is small intestinal bacterial overgrowth 
that can be managed by broad-spectrum antibiotics (10, 11). 
Although Small Intestinal Bacterial Overgrowth (SIBO) is com-
mon in patients with CVID, its diagnosis is difficult owing to con-
tinuous or interrupted use of antibiotics (11). The small intestine 
aspirate and its culture as well as Hydrogen Breath Test (HBT) are 
applied as two current clinical tests to detect SIBO. Indeed, HBT 
is a cheap, easy to use and non-invasive test. Moreover it is regard-
ed as the most popular test to diagnose SIBO in high-risk patients 
(12). The aim of this study was to assess the prevalence of SIBO 
as one of the reasons for chronic diarrhea in patients with CVID.
Materials and methods
This cross-sectional study was conducted in Rasool Akram Hos-
pital from 2009 to 2019. All patients with CVID enrolled in the 
study, according to the diagnostic criteria of ESID 2014 (13). 
This study was approved by the Ethics Committee of Iran Uni-
versity of Medical Sciences (N: IUMS.FMD.REC.1397.177). 
The inclusion criterion required was the correct preparation prior 
to perform a hydrogen breath test. 
All characteristics including demographic data and lower gastro-
intestinal symptoms (chronic diarrhea, bloating, abdominal pain, 
constipation and steatorrhea) were recorded for all patients. The 
concentration of hemoglobin was assessed. Furthermore, the level 
of IgA and IgG was measured using nephelometry (Eppendorf, 
Ecom-EG125 system, Germany) during Ig replacement therapy 
and before receiving the last dose of IVIG. To assess SIBO, HBT 
was performed using Fischer system (Lacto FAN2, Germany). 
Hydrogen Breath Test (HBT)
To do this test, patients were asked to consider some precau-
tions including (1) not taking antibiotics for 4 weeks prior to 
the test, (2) avoidance of carbohydrates foods (such as bread, 
potato and spaghetti) for 24 h before the test, (3) not taking any 
fiber supplements and laxatives 24 h before the test, (4) fasting 
for 8-12 h before the test, (5) avoidance of smoking, sleeping 
and physical activity 30 minutes before and during the test (6) 
and the use of chlorhexidine mouthwash before the test.
The baseline of breath hydrogen was evaluated for all patients. 
Then, 75 g of glucose dissolved in the water was ingested by pa-
tients. The HBT was repeated every 20 minutes for 120 minutes. 
An increase of 20 part per million (ppm) in hydrogen compared 
to baseline at least two times during 90 minutes was considered 
to be a positive test (12).  
Statistical analysis
To analyze the data, a set of quantitative and qualitative statistical tests 
available in the SPSS software version 20 (IBM, Armonk, NY, USA) 
was used. To describe the categorical variables, the frequency and per-
cent were determined. Mean ± SD and median (25th percentile (Q1), 
75th percentile (Q3)) were calculated to describe the normal and 
non-normal quantitative variables, respectively. In order to compare 
the mean difference of a quantitative variable between two depen-
dent groups, Independent t-test or Mann-Whitney test were applied. 
To evaluate the relationship between two categorical variables, Chi 
Square or Fisher Exact test were used. The significant level was con-
sidered less than 0.05. Graphpad Prism 5 (Graphpad Software Inc., 
La Jolla, CA, USA) software was applied for drawing the graphs.
Results 
The mean (± SD) age of the 27 included patients was 35.25 (± 11.69) 
years. Sixteen subjects (59.3%) were female. The mean (± SD) of 
Body Mass Index (BMI) was 22.27 ± 3.89. The median (Q1, Q3) 
duration of CVID was 9 (4, 14) year. Seven patients (25.9%) had 
a BMI less than 20.  Anemia was detected in 33.3% (n = 9) of the 
patients. Among 9 patients with anemia, four and five patients had 
microcytic anemia and normocytic anemia, respectively. In addition, 
77.8% and 25.9% of the patients with CVID showed IgA level less 
than 10 mg/dl and IgG level less than 600 mg/dl, respectively. 
Twenty patients (74.1%) presented at least one lower gastroin-
testinal symptom. The frequency of lower gastrointestinal man-
ifestations is shown in figure 1. As the figure demonstrates, the 
most frequent lower gastrointestinal symptoms were bloating 
(66.7%) and chronic diarrhea (40.7%), respectively. 
Table I shows findings of GI symptoms, clues for malabsorption 
(anemia, BMI), immunoglobulin deficiency (IgG, IgA) and GI 
comorbidities in the positive and negative HBT group. Hydro-
gen Breath Test (HBT) was positive in 40.7% (n = 11) of the pa-
tients. In the CVID patients with positive HBT, bloating, chronic 
diarrhea and abdominal pain were the most common lower GI 
manifestations. No significant difference was found in terms of 
age, BMI, IgA, IgG and duration of CVID according to the result 
of HBT. The gastrointestinal comorbidities such as Inflammatory 
Bowel Diseases (IBD) and polyposis of the ileum were reported 
through records of patients. Among the studied patients, two IBD 
cases with positive HBT, two cases with polyposis of the ileum 
(one positive HBT) and two cases with Nodular Lymphoid Hy-
perplasia (NLH) (one positive HBT) were reported. 
Some SIBO-associated symptoms such as abdominal pain and bloat-
ing were higher in HBT-positive group compared to HBT-negative 
group. A significant relationship was found between co-occurrence 
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Table I - The characteristics of CVID patients with positive and negative HBT results.
  Total Positive HBT Negative HBT P value 
Gastrointestinal Symptoms 
N (%)
Bloating   18 (66.7)     8 (72.7)   10 (62.5) 0.69
Chronic diarrhea   11 (40.7)     6 (54.5)     5 (31.3) 0.26
Abdominal pain     6 (22.2)     4 (36.4)     2 (12.5) 0.18
Constipation     4 (14.8)     1 (9.1)     3 (18.8) 0.62
Steatorrhea     3 (11.1)     2 (18.2)     1 (6.3) 0.54
Clues for malabsorption
N (%)
Anemia     9 (33.3)     5 (45.5)     4 (25) 0.41






714 (500, 770) 760 (460, 830) 700 (525, 736) 0.29
IgG < 600 mg/dl     7 (25.9)     3 (27.3)     4 (25) 1.00
IgA(mg/dl)     2 (0,6)     3 (0,6)     1 (0,15.5) 0.86





    2 (7.4)     2 (18.2)     0 (0) 0.15
Polyposis of the ileum     2 (7.4)     1 (9.1)     1 (6.3) 1.00
Nodular lymphoid 
hyperplasia
    2 (7.4)     1 (9.1)     1 (6.3) 1.00
CVID (Common Variable Immunodeficiency); HBT (Hydrogen Breath Test); GI (Gastrointestinal); 25th percentile (Q1); 75th percentile (Q3).
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of anemia and abdominal pain with positive HBT (P = 0.05) (table 
II). A positive predictive value of 100% was achieved for anemia 
accompanied with abdominal pain. Taking into account the small 
number of studied cases and the statistical results, which do not 
reach significance, it would be better to more cautiously state that 
HBT-positive patients tend to be those patients with IgG less than 
600 mg/dl and abdominal pain. Other combinations (abdominal 
pain + bloating, anemia + bloating, chronic diarrhea and IgA < 10 
mg/dl, abdominal pain and IgA < 10 mg/dl) seem to be less spe-
cific, although greater numbers are associated with HBT positivity.
Discussion
Herein, we assessed the prevalence of Small Intestinal Bacterial 
Overgrowth (SIBO) by using the Hydrogen Breath Test (HBT) 
in patients with CVID. As the results show, bloating and chronic 
diarrhea were found as the most common lower gastrointestinal 
symptoms in patients with CVID. Moreover, SIBO was detected 
in more than 40% of the patients. 
As the literature review shows, the frequency of SIBO has been 
underestimated in the last decades, resulting in misdiagnosis and 
remarkable clinical complications in patients (12, 14). There were 
some reasons for explaining this issue, including a wide spectrum 
of SIBO-related non-specific clinical symptoms, lack of consensus 
guidelines for diagnosis as well as a gold standard test to precisely 
to detect the frequency of SIBO. These issues could make the di-
agnosis and treatment more complicated and challenging. In other 
words, the accurate prevalence of SIBO and its association with a 
specific disease is unclear (12) . Although SIBO is one of the main 
and common causes of chronic diarrhea in patients with CIVD, it 
is difficult to be diagnosed because of constant or irregular antibiot-
ic usage in these patients (11).
In the current study conducted on patients with CVID, no signif-
icant relationship was found between the frequency of SIBO and 
age, gender, and duration of CVID. According to the literature, a 
relationship was found between the prevalence of SIBO and age 
and gender (15).
In this study, lower gastrointestinal manifestations were observed 
in 74.1% of the patients and bloating and chronic diarrhea were 
the two most frequently reported lower GI symptoms. In line with 
our findings, the small intestinal bacterial overgrowth often leads 
to bloating and chronic diarrhea (14). Moreover, in HBT-posi-
tive group, 81% of patients manifested symptoms associated with 
SIBO, while the others (19%) manifested none. Given that the 
symptoms related to SIBO vary in severity from asymptomatic 
to severe, it can be presumed that in asymptomatic cases, strains 
grown do not affect the gastrointestinal mucosa (12). 
Chronic diarrhea was seen in 40.7% of our patients. Hermanszewsk et 
al. reported a similar frequency (40%) of chronic diarrhea in patients 
with CVID (16). On the other hand, a higher prevalence of chronic 
diarrhea (up to 60%) was found in studies by Hemans et al. (17) and 
Atarod et al. (18). In HBT-positive cases, bloating was reported as the 
most common GI manifestation. In line with this study, Mattsson et 
al. performed breath test in a population of adult patients, who indi-
cated bloating as the most common symptom. As their study demon-
strated, 46% of patients showed positive breath test (19).
In severe cases, patients with SIBO may develop severe weight 
loss as a result of diarrhea, insufficient food intake, and most 
notably nutrient malabsorption. Deficiency of vitamins, such as 
B12 results in anemia in these patients (10, 20). As the present 
study revealed, microcytic or normocytic anemia was detected 
in 33.3% and 45.5% of CVID patients accompanying with 
positive HBT.  Although Vitamin B12 deficiency may result 
in a megaloblastic anemia in severe cases, iron deficiency has 
also been described in SIBO but the mechanisms need further 
elucidation (12). On the other hand, our cases have a chronic 
disease, and they may have anemia because of it.
Table II - The relationship between co-occurrence of clinical symptoms and Small Intestinal Bacterial Overgrowth (SIBO) in patients 
with CVID results.
Total 






Abdominal Pain and Anemia 3 (11.1) (5.06, 17.14) 3 (100) 0 (0) 0.05
Abdominal Pain and Bloating 6 (22.2) (6.53, 37.87) 4 (66.7) 2 (33.3) 0.18
Anemia and Bloating 6 (22.2) (6.53, 37.87) 4 (66.7) 2 (33.3) 0.18
Chronic Diarrhea and IgA < 10 9 (33.3) (15.6, 51) 5 (55.6) 4 (44.4) 0.41
Chronic Diarrhea and IgG < 600 2 (7.4) (-2.47, 17.27) 1 (50) 1 (50) 1.00
Abdominal pain and IgA < 10 4 (14.8) (1.5, 28.1) 3 (75) 1 (25) 0.27
Abdominal pain and IgG < 600 2 (7.4) (-2.47, 17.27) 2 (100) 0 (0) 0.15
CVID (Common Variable Immunodeficiency); HBT (Hydrogen Breath Test).
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There is a positive relationship between anemia and other symp-
toms associated with SIBO since the co-occurrence of anemia with 
abdominal pain was significantly higher in patients with SIBO. 
Positive predictive value of 100% was obtained for anemia accom-
panied by abdominal pain, which can provide a clue to SIBO di-
agnosis. A higher incidence of SIBO in patients with abdominal 
pain + bloating, anemia + bloating, abdominal pain + IgG < 600, 
IgA less than 10 mg/dl + diarrhea as well as IgA less than 10 mg/dl 
and abdominal pain was observed. This finding is consistent with 
previous studies suggesting that GI infections are more common 
in patients with undetectable serum IgA level (21). 
In this study, two limitations need to be considered. Firstly, the 
frequent use of antibiotics in patients with CVID owing to un-
derlying diseases decreased the number of the patients able to 
perform the HBT, thereby leading to small sample size. Second-
ly, the exclusion of some patients due to respiratory problems 
and inability to perform HBT, reduced the number of the pa-
tients. Moreover, cross-sectional design of the study might also 
underestimate the number of patients with SIBO.
Conclusions
Regarding the findings of the current cross-sectional study, 
bloating and chronic diarrhea were considered as the most com-
mon lower gastrointestinal symptoms in patients with CVID 
and SIBO was detected in more than 40% of these patients. 
Moreover, a 100% positive predictive value for anemia accom-
panied with by abdominal pain. Notwithstanding the limita-
tions due to the small number of cases, gastrointestinal symp-
toms and routine clinical evaluation arise as potential valuable 
diagnostic clues. Timely and precise diagnosis of SIBO may lead 
to appropriate management of manifestations using broad-spec-
trum antibiotics and thereby preventing weight loss and malab-
sorption stemmed from diarrhea and finally improve the quality 
of life in these patients. 
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